RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components

被引:29
作者
Mochizuki, Kunio
Kondo, Tetsuo
Nakazawa, Tadao
Iwashina, Masanori [2 ]
Kawasaki, Tomonori
Nakamura, Nobuki [3 ]
Yamane, Tetsu
Murata, Shin-ichi [4 ]
Ito, Koichi [5 ]
Kameyama, Kaori [6 ]
Kobayashi, Makio [7 ]
Katoh, Ryohei [1 ]
机构
[1] Univ Yamanashi, Dept Pathol, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, Yamanashi 4093898, Japan
[2] Nishigunma Natl Hosp, Dept Clin Lab, Gunma, Japan
[3] Tokyo Med & Dent Univ, Dept Pathol, Tokyo, Japan
[4] Saitama Med Univ, Dept Pathol, Saitama, Japan
[5] Ito Hosp, Div Surg, Tokyo, Japan
[6] Keio Univ Hosp, Div Pathol Diag, Tokyo, Japan
[7] Tokyo Womens Med Univ, Dept Pathol, Tokyo, Japan
关键词
anaplastic transformation; BRAF mutation; papillary thyroid carcinoma; RET rearrangements; undifferentiated thyroid carcinoma; POORLY DIFFERENTIATED CARCINOMAS; HIGH PREVALENCE; RET/PTC REARRANGEMENTS; ANAPLASTIC CARCINOMA; ONCOGENE ACTIVATION; TUMORS; CANCER; GENE; TRANSVERSION; EXPRESSION;
D O I
10.1111/j.1365-2559.2010.03646.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To elucidate the genetic background of anaplastic transformation, RET rearrangements and BRAF mutation were studied in composite undifferentiated carcinomas (UCs) of the thyroid, which are UCs having papillary carcinoma (PC) components. Methods and results: Reverse transcription-polymerase chain reaction (RT-PCR) was performed for RET rearrangements and PCR for BRAF mutation in UC and PC components that were microdissected separately from seven composite UCs. Forty-two thyroid cancers with single component histology (14 UCs and 28 PCs) were also studied in the same manner. RET/PTC1 was undetectable in both components from all seven composite UCs, and RET/PTC3 was identified in both components of one composite UC. BRAF mutation was identified in both components from three composite UCs and only in the PC components from two composite UCs. In contrast, in thyroid carcinomas with single component histology, RET/PTC1 was detected in 11% of PCs and in none of the UCs, and RET/PTC3 was not found in any of the tumours studied. BRAF mutation was identified in 82% of PCs and in 21% of UCs. Conclusions: The high frequency of BRAF mutation and the absence of RET rearrangements in UC components from composite UCs supports the hypothesis that UCs may actually represent progressive malignant degeneration of a BRAF-mutated, well-differentiated thyroid carcinoma.
引用
收藏
页码:444 / 450
页数:7
相关论文
共 40 条
  • [21] RET/PTC rearrangement in thyroid tumors
    Nikiforov, YE
    [J]. ENDOCRINE PATHOLOGY, 2002, 13 (01) : 3 - 16
  • [22] Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas
    Nikiforov, YE
    [J]. ENDOCRINE PATHOLOGY, 2004, 15 (04) : 319 - 327
  • [23] BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
    Nikiforova, MN
    Kimura, ET
    Gandhi, M
    Biddinger, PW
    Knauf, JA
    Basolo, F
    Zhu, ZW
    Giannini, R
    Salvatore, G
    Fusco, A
    Santoro, M
    Fagin, JA
    Nikiforov, YE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) : 5399 - 5404
  • [24] RET/PTC activation in hyalinizing trabecular tumors of the thyroid
    Papotti, M
    Volante, M
    Giuliano, A
    Fassina, A
    Fusco, A
    Bussolati, G
    Santoro, M
    Chiappetta, G
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (12) : 1615 - 1621
  • [25] BRAF and endocrine tumors:: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors
    Perren, A
    Schmid, S
    Locher, T
    Saremaslani, P
    Bonvin, C
    Heitz, PU
    Komminoth, P
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (04) : 855 - 860
  • [26] Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas
    Porra, V
    Ferraro-Peyret, C
    Durand, C
    Selmi-Ruby, S
    Giroud, H
    Berger-Dutrieux, N
    Decaussin, M
    Peix, JL
    Bournaud, C
    Orgiazzi, J
    Borson-Chazot, F
    Dante, R
    Rousset, B
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) : 3028 - 3035
  • [27] BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas
    Puxeddu, E
    Moretti, S
    Elisei, R
    Romei, C
    Pascucci, R
    Martinelli, M
    Marino, C
    Avenia, N
    Rossi, ED
    Fadda, G
    Cavaliere, A
    Ribacchi, R
    Falorni, A
    Pontecorvi, A
    Pacini, F
    Pinchera, A
    Santeusanio, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) : 2414 - 2420
  • [28] Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations
    Quiros, RM
    Ding, HG
    Gattuso, P
    Prinz, RA
    Xu, XL
    [J]. CANCER, 2005, 103 (11) : 2261 - 2268
  • [29] RET ONCOGENE ACTIVATION IN HUMAN THYROID NEOPLASMS IS RESTRICTED TO THE PAPILLARY CANCER SUBTYPE
    SANTORO, M
    CARLOMAGNO, F
    HAY, ID
    HERRMANN, MA
    GRIECO, M
    MELILLO, R
    PIEROTTI, MA
    BONGARZONE, I
    DELLAPORTA, G
    BERGER, N
    PEIX, JL
    PAULIN, C
    FABIEN, N
    VECCHIO, G
    JENKINS, RB
    FUSCO, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (05) : 1517 - 1522
  • [30] Sedliarou I, 2004, INT J ONCOL, V25, P1729